Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › bexagliflozin

bexagliflozin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of bexagliflozin

12 trials tracked of bexagliflozin: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 26 citations.

12Trials tracked
6Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 6 Phase 1 6
  1. Phase 3 Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Completed · 26 cited
  2. Phase 3 Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes Completed
  3. Phase 3 Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Completed
  4. Phase 3 Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Completed
  5. Phase 3 Bexagliflozin Efficacy and Safety Trial Completed
  6. Phase 3 An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension Completed
Show 6 more trials
  1. Phase 1 Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection Completed
  2. Phase 1 Bexagliflozin Drug/Drug Interaction Study With Digoxin Completed
  3. Phase 1 Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects Completed
  4. Phase 1 Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment Completed
  5. Phase 1 Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Completed
  6. Phase 1 Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SGLT2 and dual SGLT1/2 inhibitors reduce cardiovascular death or heart failure hospitalization risk in type 2 diabetes patients
Diabetes & Endocrinology Meta-analysis
SGLT2 and dual SGLT1/2 inhibitors reduce cardiovascular death or heart failure hospitalization risk in type 2 diabetes patients Three diabetes drugs lower heart failure and heart attack risk
This network meta-analysis evaluates bexagliflozin, ertugliflozin, and sotagliflozin versus placebo for patients with type 2 diabetes. The a…
Three newer diabetes drugs cut heart failure and heart attack risk in people with type 2 diabetes, a new analysis finds.
Jun 1, 2026
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes New analysis shows bexagliflozin helps lower blood sugar and weight in adults with type 2 diabetes compared to other drugs
This systematic review and network meta-analysis synthesized evidence on bexagliflozin versus other SGLT2 inhibitors and placebo in adults w…
A large review of 26,838 patients found bexagliflozin lowers blood sugar and weight well. It also lowers blood pressure and causes fewer inf…
Frontiers May 13, 2026